Logo

Three Pharma Companies Launch Favipiravir to Treat COVID-19 in India

Share this

Three Pharma Companies Launch Favipiravir to Treat COVID-19 in India

Shots:

  • Jenburkt became the second company to launch Favivent (favipiravir) to treat mild to moderate COVID-19 symptoms at a price of ​Rs. 39/tablet
  • Cipla receives the DCGI approval for Ciplenza (favipiravir- 200mg) targeting the unmet medical needs for COVID-19 treatment options in the country through restricted emergency use. The company will launch Ciplenza in the first week of August priced at Rs 68/ tablet
  • Moreover- Brinton gets DCGI approval drug favipiravir under the brand name Faviton (Rs 59/ tablet) for the treatment of COVID-19 patients. Faviton is a generic version of Avigan of Fujifilm Toyama- a subsidiary of Fujifilm Corporation

Cipla- Jenburkt- Brinton­  Ref: Cipla- Jenburkt- Brinton | Image: Pharmashots

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions